Human and Avian Influenza Whole Genome Phage Display Libraries
Description of Invention:
Available for use in developing research reagents, therapeutics or diagnostics are recombinant bacteriophage display libraries for identifying influenza viral gene products in preparation for pandemic threats the cross-reactivity and long-term protection of interpandemic influenza vaccines. Influenza vaccines predominantly include haemagglutinin (HA) and Neuraminidase (NA) antigens that characterize annual circulating influenza types A and type B. Analyses of the immune responses against new candidate vaccines is required in order to identify the best correlate of protection against seasonal human influenza strains and potential pandemic strains.
These "Whole Viral Genome Phage Display Libraries" express complete sets of protein fragments encoded by several Human and Avian Influenza strains including HlN1, H3N2, H5N1 and H7N7 and can be used for in depth analyses of plasma samples from: a) individuals exposed to human influenza; b) individuals exposed to avian influenza; c) individuals vaccinated with traditional influenza vaccines; d) individuals vaccinated with new generation vaccines against human and bird influenza viruses.
Applications:
Serological assays for surveillance of pandemic influenza outbreaks
Serological assays for distinguishing between exposure to human and bird influenza strains
Serological assays for diagnosing true infections in previously vaccinated individuals
Rapid analyses of immune sera from pre-clinical and clinical trials of novel influenza vaccines
Mapping of monoclonal and polyclonal antibodies against different influenza gene products
Identification of highly conserved "protective" epitopes for inclusion in future broadly-reactive influenza vaccines (against either inter-pandemic or pandemic influenza strains)
Studies of viral protein-protein, viral RNA-protein and viral-host protein interactions (viral pathogenesis studies)
Market:
Influenza diagnostics and vaccines
Development Status:
Materials available as research tools
Scientific Contact:
Hana Golding, Ph.D.; FDA/CBER/OVRR/DVP/LR; 9000 Rockville Pike, Building 29B, Room 4N04, Bethesda, MD 20892; Email:
goldingh@cber.fda.gov; Phone: 301/827-0784
Inventors: Hana Golding and Surender Khurana (FDA)
Patent Status:
DHHS Reference No. E-031-2007/0 – Research Tool
Licensing Status: Available for licensing as a biological material.
For Additional Information Please Contact: Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220
